Our findings confirmed that HSP90AB1 overexpression could enhance the tolerance of ovarian cancer cells to chemotherapeutic agents by activating drug-resistant proteins IGF1R and MYC, affecting the prognosis of patients. This evidence concerns the gene IGF1R and ovarian cancer.